Am­gen sweeps last BC­MA BiTE stand­ing out of pipeline

Ex­act­ly a year af­ter re­sum­ing dos­ing on a bis­pe­cif­ic that hits BC­MA, Am­gen is scrap­ping the drug al­to­geth­er for “strate­gic rea­sons.”

The move — along with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER